MedDo Technology Reports Full Year 2025 Net Profit of RMB 72.709 Million, Achieving Turnaround from Loss to Profitability

According to Hong Kong Stock Exchange announcements on June 30, MedDo Technology reported full year 2025 net profit attributable to shareholders of RMB 72.709 million, marking a historic turnaround from previous losses to profitability. In related listings, Baoji Pharma-B (02659) received approval from China's NMPA for BJ044 injection (recombinant Ulinastatin) clinical trial application. Additionally, Guanghetype (00638) proposed to acquire 37.16% equity stake in Hangsheng Electronics for RMB 1.428 billion, pursuing vertical integration of communication modules and automotive electronic systems.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments